In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new CAR-T cell therapy, Kymriah, and the issues around pricing for this revolutionary treatment.
* Please note that this interview was conducted in October 2017. Bruno Strigini has subsequently announced that he will retire from Novartis Oncology in early 2018.
Novartis is notable for being the first of the big pharma firms to assemble a global business unit dedicated solely to developing and launching innovative oncology medicines. Why was it deemed necessary to adopt this sort of corporate structure of a ‘firm within a firm’? What advantages does it bring?
Looking at our productivity in 2017 alone, which includes three new therapy approvals, it is clear that the model we established makes good sense
